Is ‘Glicked’ the new ‘Barbenheimer’? ‘Wicked’ and ‘Gladiator II’ collide in theaters

“Barbenheimer” was a phenomenon impossible to manufacture. But, more than a year later, that hasn’t stopped people from trying to make “Glicked” — or even “Babyratu” — happen. The counterprogramming of “Barbie” and “Oppenheimer” in July 2023 hit a nerve culturally and had the receipts to back it up. Unlike so many things that begin…

Read More

Baidu shares slide as Barclays downgrades on ad revenue outlook

Investing.com — Baidu (NASDAQ:BIDU) US-listed shares fell nearly 3% in premarket trading Friday after Barclays (LON:BARC) analysts downgraded the stock to Equal Weight from Overweight and cut the price target from to $83 from $115. The revision comes amid pressures from the Chinese internet giant’s growing focus on generative AI, which “exacerbates pressure” on advertising…

Read More

Barclays says buy Novo Nordisk stock ‘into this critically important catalyst’

Investing.com — Barclays analysts are bullish on Novo Nordisk (NYSE:NVO) stock ahead of the December release of pivotal clinical trial data for its next-generation obesity treatment, CagriSema. The results of the REDEFINE-1 Phase 3 trial could, according to Barclays (LON:BARC), “redefine the obesity landscape” and provide a much-needed boost to the company’s stock, which has faced…

Read More